Skip to content

Role of injectable blood derivative and LASER for treatment of muscular pain in facial region.

Comparative Effectiveness of Injectable platelet-rich Plasma, Photo biomodulation Therapy, and Sequential Application of Platelet-Rich Plasma Followed by Photo biomodulation in management of myofascial trigger points in masseter muscle A randomized clinical trial - NIL

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/01/101942
Enrollment
69
Registered
2026-01-23
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M791- Myalgia

Interventions

Intervention1: Injectable PRP followed by PBM: Procedure to prepare PRP Liquid PRP will be prepared according to the PRP preparation protocol 8 A tourniquet tied to the patients arm and a 70 percent i

Sponsors

Post Graduate Institute of Dental Sciences Rohtak
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Patients diagnosed with myofascial pain as per DC TMD Ib with active trigger points involving masseter muscle 2 Patients consent for participation in the study

Exclusion criteria

Exclusion criteria: 1 Patients with a phobia to needles 2 Patients who have undergone previous treatment for myofascial pain 3 Patients with active infection at the site of injection or overlying skin 4 Patients with a history of trauma to the maxillofacial region in past 6 months 5 Patients with other types of orofacial pain and musculoskeletal disorders. 6 Patients with parafunctional habits 7 Healing disorders or systemic diseases where healing is compromised 8 Patients on anticoagulant therapy 9 Bleeding and clotting disorders 10 Patients with epilepsy seizures 11 Pregnancy and lactation 12 Patients addicted to alcohol drugs 13 BDI in moderate and severe category

Design outcomes

Primary

MeasureTime frame
NRS for assessment of pain score MO, PM, RTLEM, and LTLEM in mm for evaluation of functional movements. Timepoint: Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks and 3 months.

Secondary

MeasureTime frame
To assess patient satisfaction (Likert scale) To evaluate the need for alternative treatment in both groups (as frequency) To evaluate the side effects of injectable platelet rich plasma, photobiomodulation if any (as frequency) Timepoint: Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks and 3 months.

Countries

India

Contacts

Public ContactDr Sharika C.S.

PGIDS, Rohtak

sharikacs19@gmail.com8943557802

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026